Genocea Biosciences Inc · OTC:GNCAQ
Genocea Biosciences — Investor Presentation (January 2019)
24 slides from Genocea Biosciences's investor presentation, Jan 7, 2019
Slide 1: Beyond Machines for Antigen Selection: Using ATLAS to Enable Novel Cancer Immunotherapies
Beyond Machines for Antigen Selection: Using ATLAS™ to Enable Novel Cancer Immunotherapies January 2019
Slide 2: Disclaimer
Disclaimer This presentation contains “forward-looking” statements that are within the meaning of federal securities laws and are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning our poss
Slide 3: Selecting the right antigens to enable diverse cancer immunotherapies
Selecting the right antigens to enable diverse cancer immunotherapies: POWERFUL NOVEL UNIQUE ADVANTAGE TECHNOLOGY IMMUNOTHERAPIES ATLAS™ We Know, They • Vaccines & T cell Platform Guess therapies; …based on actual patient- • Neoantigen and shared …validated in screening of and antigen-specific ~200
Slide 4: Compelling investment opportunity
Compelling investment opportunity CLINICAL-STAGE cancer immunotherapy company UNIQUE antigen selection platform, ATLAS™ – Personalized tumor, immune repertoire profiling for better antigen selection – Better antigens critical to delivering on promise of neoantigen immunotherapies VALIDATING clinical
Slide 5: Next-gen therapies can extend the immuno-oncology revolution
Next-gen therapies can extend the immuno-oncology revolution FOUNDATIONAL PROMISE VS. OUR OPPORTUNITY THERAPEUTICS REALITY Immune checkpoint inhibitors (ICI) ICI CAR-T Next-generation immunotherapies that direct or deliver T cells to kill tumors • Efficacy limited to • Efficacy limited to CAR-T cert
Slide 6: T cells directed to the correct targets are integral to successful immunotherapies
T cells directed to the correct targets are integral to successful immunotherapies Vaccines Adoptive cell therapy (ACT) (Neo) Antigen (Neo) Antigen Antigen-specific Phenotype Modality Discovery and and and EXPANSION DELIVERY SELECTION Which antigens can/should the immune system respond to? Most Inno
Slide 7: In silico antigen selection renders vaccines sub-optimally immunogenic
In silico antigen selection renders vaccines sub-optimally immunogenic Properties [Neon]*1 BioNTech*2 Moderna3 Aduro4 Synthetic long peptides + Vaccine mRNA mRNA Listeria Poly-ICLC adjuvant Immunogenicity CD4+ responses: 20% CD4+ responses: 21%^ 2 pos. neoantigen pools 1 of 14 pos. neoantigen from (
Slide 8: Only ATLAS personalizes profiles of both tumor and T cell responses
Only ATLAS™ personalizes profiles of both tumor and T cell responses THE CHALLENGE Identifying true neoantigens: Antigens triggering anti-tumor T cell responses CANCER PATIENTS ATLAS™ T cell Recognized by T cells T cell receptor Neoantigen 0111100 00010110 MHC Molecule IN SILICO PeptidesPeptides Pre
Slide 9: ATLAS: Identifying true neoantigens based on patients' own T cell responses
ATLAS™: Identifying true neoantigens based on patients’ own T cell responses INPUT: Patient’s own antigen E. coli presenting cells Every potential neoantigen cLLO from Patient’s own Phagocytosis patient tumor T cells recall neoantigens Phagosome without Phagolysosome (pH drop) predictions Potential
Slide 10: ATLAS is a rapid, industrialized platform for antigen discovery
ATLASTM is a rapid, industrialized platform for antigen discovery Neoantigen Targets TAA/Viral Targets ~200 cancer patients’ samples Dendritic Cell screened 10 T cell
Slide 11: ATLAS identifies and characterizes all candidates to identify true neoantigens
ATLAS™ identifies and characterizes all candidates to identify true neoantigens NSCLC PATIENT 52 candidate neoantigens identified & profiled IFNγ responses depicted CD8+ T cells CD4+ T cells True neoantigens – selected for therapy Not antigens “Inhibitory” neoantigens- excluded from therapy Candidat
Slide 12: Inhibitory neoantigens suppress immune responses, may promote tumor progression
“Inhibitory” neoantigens suppress immune responses, may promote tumor progression mATLAS CD8+ screen Study Design Stimulatory antigen vaccination Vaccine Typical endpoint s.c. >200mm2 D0 D3 D10 D17 B16F10 s.c. Inhibitory antigen vaccination TIL g PBS Inhibitory 8000 6000 4000 CD8 Cell count 2000 DAP
Slide 13: Profiling patient tumor and immune response repertoire with ATLAS yields vastly different antigen sets
Profiling patient tumor and immune response repertoire with ATLAS yields vastly different antigen sets 0111100 01 10010110 11 0100111 010 1 ININ- SILICOSILICO EX VIVO 11101 01110 10 01111001011 2 011 1100 NetMHCpan Predicted BIOLOGY TOO COMPLEX ATLAS™ FOR THESE APPROACHES “Inhibitory” Stimulatory ID
Slide 14: GEN-009: ATLAS neoantigen selection for personalized cancer vaccines
GEN-009: ATLAS™ neoantigen selection for personalized cancer vaccines Collect tumor and blood ATLAS to identify true SYNTHESIZE VACCINE Ship personalized product to samples, sequence exome neoantigens of CD4+ and (synthetic long peptides + Poly clinical site CD8+ ICLC) with T cell responses ATLAS-id
Slide 15: GEN-009 clinical trial designed to demonstrate superiority of ATLAS antigen selection
GEN-009 clinical trial designed to demonstrate superiority of ATLAS™ antigen selection in patients PHASE 1/2a STUDY OVERVIEW1 PART A PART B • Patient cohort: No evidence of disease, high risk of • Multiple cohorts: ICI combo with stable disease, relapse partial responses • Multiple tumor types with
Slide 16: GEN-011 has potential to improve on other ACT approaches
GEN-011 has potential to improve on other ACT approaches TIL therapy GEN-011 TCR transduced T cells CAR-T Remarkable efficacy in some patients Limited to tumors with high TMB and TIL content Emerging for solid tumors Issues with off-tumor on-target effects Hematologic cancers Limited HLA Less succes
Slide 17: GEN-011 is a first-in class personalized non-engineered ACT targeting multiple neoantigens
GEN-011 is a first-in class personalized non-engineered ACT targeting multiple neoantigens • Product is autologous, ATLAS-identified neoantigen-expanded peripheral blood T cells (CD4+ and CD8+) – Multiple specificities for broader coverage, reduced potential for escape – Both CD4+ and CD8+ T cells w
Slide 18: GEN-011: ATLAS neoantigen selection for personalized T cell therapy
GEN-011: ATLAS™ neoantigen selection for personalized T cell therapy ATLAS true neoantigen identification Neoantigen-specific T cell expansion Neoantigen list NGS Mutant antigen library in E. coli ATLAS-defined neoantigens Tumor + + cytokine(s) ATLAS neoantigen identification + (CD4+ and CD8+ Autolo
Slide 19: GEN-011: a differentiated ACT approach
GEN-011: a differentiated ACT approach Neoantigen-specific TCR Features/Benefits GEN-011 TIL ACT TAA-specific ACT ACT Potential for better immunogenicity, efficacy Broad neoantigen coverage Self, not neoantigens CD4+ and CD8+ antigens Single antigen specificity HLA agnostic Rule out inhibitory antig
Slide 20: ATLAS drives deep emerging Genocea neoantigen immunotherapy pipeline
ATLAS™ drives deep emerging Genocea neoantigen immunotherapy pipeline1 DISCOVERY PRE-IND PHASE 1/2a PIVOTAL STATUS & ANTICIPATED MILESTONES GEN-009 • Immunogenicity data in 1st Generation late Q2/early Q3 Neoantigen Cancer Vaccine • Clinical efficacy in 2020 GEN-010 Proprietary vaccine 2nd Generatio
Slide 21: Team with deep vaccinology, immunology and cancer experience
Team with deep vaccinology, immunology and cancer experience Girish Aakalu, PhD Pamela Carroll, PhD Chief Business Officer SVP, Immuno-oncology Chip Clark Tom Davis, MD President & CEO Chief Medical Officer Jessica Baker Flechtner, PhD Derek Meisner Chief Scientific Officer SVP, General Counsel Nari
Slide 22: Seasoned SAB and board
Seasoned SAB and board SCIENTIFIC ADVISORY BOARD BOARD Chuck Drake, MD, PhD Ken Bate (Chair) Former chair, Cubist Ex-Biogen, Millennium Director of Genitourinary Oncology President Ali Behbahani, MD, PhD General partner, NEA Elizabeth Jaffee, MD CEO, Editas Chair Katrine Bosley Deputy Director Forme
Slide 23: Compelling investment opportunity
Compelling investment opportunity CLINICAL-STAGE cancer immunotherapy company UNIQUE antigen selection platform, ATLAS™ – Personalized tumor, immune repertoire profiling for better antigen selection – Better antigens critical to delivering on promise of neoantigen immunotherapies VALIDATING clinical
Slide 24: Genocea Biosciences, Inc.
Genocea Biosciences, Inc. NASDAQ: GNCA 100 Acorn Park Drive Cambridge, MA 02140 USA Phone: +1 617.876.8191 www.genocea.com
Genocea Biosciences — Investor Presentation (January 2019) on 6ix